NSCLC is the largest disease at ASCO 2026 by trial count, abstract count, and patient population — consistently ~20-25% of the oncology presentation slate. For a typical newly-diagnosed metastatic NSCLC patient in 2026, the standard of care depends heavily on biomarker testing: EGFR-mutant patients start on osimertinib (or other 3rd-gen EGFR TKI); ALK-positive on alectinib or lorlatinib; KRAS G12C on sotorasib or adagrasib after first-line failure; PD-L1 high (TPS ≥50%) on pembrolizumab monotherapy; PD-L1 low or other histology on pembrolizumab plus platinum doublet chemotherapy.
But this established taxonomy is being challenged on multiple fronts in 2026:
This blog walks through the 1L and adjuvant Phase 3 trials most likely to drive media coverage at ASCO 2026, and what NSCLC patients should ask their oncologist this week.
Two TROP2 antibody-drug conjugates are in head-to-head Phase 3 trials testing whether adding them to pembrolizumab beats pembrolizumab alone in first-line non-driver-mutated NSCLC. The TROP2 protein is broadly expressed on NSCLC tumor cells; the ADCs deliver topoisomerase I inhibitor payload (deruxtecan or belotecan derivatives) selectively to TROP2-expressing cells.
NCT05215340 tests datopotamab deruxtecan (Dato-DXd) plus pembrolizumab versus pembrolizumab alone in first-line metastatic NSCLC with PD-L1 high (TPS ≥50%) without actionable genomic alterations. The Phase 3 follows the Phase 1b TROPION-Lung02 signal of dato-DXd + pembrolizumab and Phase 3 TROPION-Lung01 (dato-DXd vs docetaxel in pretreated NSCLC). Why patients should care: if positive, this would be the first ADC + IO combination to potentially displace pembrolizumab monotherapy in PD-L1-high NSCLC — a setting where pembrolizumab has been the dominant standard since 2016.
NCT06170788 tests sacituzumab tirumotecan (MK-2870, the Merck-licensed TROP2 ADC; same compound also known as SKB264 outside Merck's territory) plus pembrolizumab versus pembrolizumab in first-line metastatic NSCLC with PD-L1 high (TPS ≥50%). This is the direct head-to-head competitor to TROPION-Lung08 — same indication, similar comparator. What to watch at ASCO: interim safety data, biomarker subgroups (PD-L1 score correlation with TROP2 expression).
Both trials have read-out potential within 12-18 months of ASCO 2026. The first positive readout for either compound + pembrolizumab will reshape 1L NSCLC immediately.
Since the FLAURA trial established osimertinib as the standard 1L EGFR-mutant NSCLC therapy in 2017, the field has accumulated combination strategies. FLAURA2 (osimertinib + chemo) and MARIPOSA (amivantamab + lazertinib) both showed PFS improvements over osimertinib alone. ASCO 2026 brings the next generation: osimertinib + ADC combinations, new EGFR TKIs, and updated HER2-mutant ADC data.
NCT06350097 tests datopotamab deruxtecan plus osimertinib versus osimertinib alone in first-line EGFR-mutant metastatic NSCLC. The hypothesis is that ADC-mediated cytotoxic delivery alongside EGFR TKI provides complementary anti-tumor activity and delays acquired resistance. Patient note: this is the first 1L EGFR-mutant trial combining osimertinib with an ADC in Phase 3. If positive, it shifts the EGFR-mutant 1L standard away from oral-only therapy.
NCT06417814 is the post-progression sibling study — dato-DXd with or without osimertinib continuation in EGFR-mutant patients who have progressed on prior osimertinib. Tests whether adding the TROP2 ADC at the 2L+ transition delays subsequent progression, with the ± osimertinib question addressing whether continuing the EGFR TKI through resistance adds benefit.
NCT06899126 tests trastuzumab deruxtecan (T-DXd) plus pembrolizumab plus platinum-based chemotherapy in first-line HER2-mutated metastatic NSCLC. T-DXd already has accelerated FDA approval (DESTINY-Lung02) for previously-treated HER2-mutant NSCLC; this Phase 3 tests it in 1L combined with IO + chemo backbone.
NCT06452277 tests sevabertinib (a HER2-targeted tyrosine kinase inhibitor) in HER2-mutant NSCLC. Different mechanism than T-DXd (TKI vs ADC); offers an oral, biomarker-targeted option for the HER2-mutant subgroup (~2% of NSCLC).
NCT07010419 tests firmonertinib (also known as furmonertinib in China) versus placebo in EGFR-mutant NSCLC. Firmonertinib is a 3rd-generation EGFR TKI with CNS activity, already approved in China; this is the ArriVent global pivotal trial. The companion FORWARD trial (NCT04853342) tests firmonertinib in a different EGFR-mutant population.
KRAS mutations occur in approximately 25% of NSCLC adenocarcinomas. The G12C-specific inhibitors sotorasib and adagrasib received FDA approval based on KRYSTAL-12 and CodeBreaK 200 in pretreated G12C-mutant NSCLC. ASCO 2026 brings the next wave: pan-RAS inhibitors that hit multiple KRAS subtypes, combination strategies with IO, and movement of KRAS-targeting into the adjuvant resected setting.
NCT06881784 tests daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor that targets the active GTP-bound state of multiple RAS variants — including G12X variants (G12D, G12V, G12C, G12R) and Q61X variants — as well as wild-type RAS. This is a substantial expansion beyond the G12C-only inhibitors sotorasib and adagrasib. The Revolution Medicines Phase 2 readout in advanced PDAC was the major pre-ASCO 2026 story; the NSCLC pivotal Phase 3 follows. Patient note: this is the first pan-RAS-class inhibitor in a Phase 3 NSCLC trial. See the dedicated daraxonrasib drug page for the full trial list across cancers.
NCT06793215 tests divarasib (a KRAS G12C inhibitor) plus pembrolizumab versus standard chemoimmunotherapy in first-line KRAS G12C-mutant metastatic NSCLC. Tests whether the targeted KRAS inhibitor can replace the chemotherapy component of the IO + chemo standard. If positive, KRAS G12C patients could move to all-oral KRAS-targeted + IO combination as 1L.
NCT07431827 tests calderasib (MK-1084, Merck's KRAS G12C inhibitor) plus pembrolizumab in completely resected stage IIA-IIIB (N2) KRAS G12C-mutant NSCLC. Moves KRAS-targeting into the curative-intent adjuvant setting — potentially offering KRAS G12C patients an oral targeted option after surgery alongside the standard adjuvant IO.
Ivonescimab (AK112, the Akeso / Summit Therapeutics PD-1 × VEGF bispecific antibody) showed superiority over pembrolizumab in HARMONi-2 in late 2024 for first-line PD-L1-positive NSCLC. ASCO 2026 expands the ivonescimab Phase 3 footprint into additional 1L populations and post-progression settings, plus competition from other PD-1/VEGF bispecifics (rilvegostomig from AstraZeneca; pumitamig).
NCT06767514 tests ivonescimab versus pembrolizumab-based regimens in first-line metastatic NSCLC. This builds on the HARMONi-2 head-to-head readout (ivonescimab monotherapy vs pembrolizumab monotherapy) from late 2024 that established ivonescimab's PFS superiority over pembrolizumab in PD-L1-positive NSCLC. Positive HARMONi-7 readout would extend ivonescimab's competitive position beyond the PD-L1-positive monotherapy setting.
See the dedicated ivonescimab drug page for the full Phase 3 footprint across NSCLC, cervical, gastric, and other indications.
NCT06928389 tests ivonescimab plus docetaxel in advanced NSCLC after 1L failure. Different setting (2L+) from HARMONi-7 but tests whether the PD-1/VEGF bispecific paired with chemo improves outcomes vs docetaxel alone in the IO-pretreated population.
NCT06868277 tests rilvegostomig (AstraZeneca's PD-1 × TIGIT bispecific) versus pembrolizumab monotherapy in first-line metastatic NSCLC. Different bispecific target (TIGIT instead of VEGF) but similar competitive positioning vs pembrolizumab. See the dedicated rilvegostomig drug page for the full Phase 3 footprint across multiple cancers.
Adjuvant immunotherapy after surgical resection has been an active area since the CheckMate-816 (neoadjuvant nivolumab + chemo) and KEYNOTE-671 (perioperative pembrolizumab + chemo) trials established peri-surgical IO as standard for resectable NSCLC. ASCO 2026 brings the next wave: combining adjuvant IO with personalized mRNA cancer vaccines.
NCT06077760 tests intismeran autogene (V940, the Moderna individualized neoantigen mRNA cancer vaccine) plus pembrolizumab versus pembrolizumab alone as adjuvant therapy after complete resection of stage II-IIIB NSCLC. Builds on the V940 + pembrolizumab adjuvant melanoma Phase 2 results from 2023 that showed substantial recurrence-free survival benefit. Patient note: this is a personalized vaccine — each patient receives a custom-manufactured mRNA encoding ~34 neoantigens specific to their resected tumor.
NCT07513376 is the sibling trial testing V940 monotherapy or with pembrolizumab in adjuvant NSCLC. Together with INTerpath-002, defines the role of personalized mRNA cancer vaccines in the resected NSCLC setting.
NCT06765109 tests neladalkib (NVL-655, the Nuvalent next-generation ALK inhibitor) in TKI-naive ALK-positive advanced NSCLC. Neladalkib is designed to maintain potency against the G1202R resistance mutation and offer improved CNS penetration vs prior-generation ALK TKIs. Patient note: ALK-positive NSCLC patients have been well-served by alectinib and lorlatinib; ALKAZAR tests whether the next-generation TKI offers further improvements at the 1L step.
Patritumab deruxtecan (HER3-DXd), the Daiichi Sankyo HER3-targeted ADC, has Phase 3 trials in EGFR-mutant NSCLC after osimertinib progression. See the dedicated HER3-DXd drug page for the full trial list across cancers.
NSCLC at ASCO 2026 is a story of five competing 1L challenger strategies to the current pembrolizumab-anchored standard: TROP2 ADCs (TROPION-Lung08, TroFuse-007), PD-1/VEGF bispecifics (HARMONi-7 ivonescimab), KRAS-targeted combinations (Krascendo 2 divarasib + pembrolizumab), personalized mRNA vaccines (INTerpath-002 V940 + pembrolizumab), and EGFR-mutant ADC combinations (TROPION-Lung14 Dato-DXd + osimertinib).
For patients, the implication is that first-line NSCLC therapy in 2027-2028 will likely be more biomarker-tailored and combination-based than the current 2026 standard. The right question to ask your oncologist today is not "which standard regimen am I getting?" but "given my driver mutation status, PD-L1 score, TROP2 expression, and KRAS subtype, which open Phase 3 trial best matches my profile?"
Find Your NSCLC Trial Match
Use ClinTrialFinder's AI-powered matching to find NSCLC trials based on your specific biomarkers, line of therapy, and disease burden.
Find Matching NSCLC Trials